Dr Talal Al-Mayhani
http://al-mayhani-english.blogspot.co.uk (personal home page)
Glioblastoma (GBM) is the most common type of primary brain malignancies. Patients face dismal prognosis with survival rate of less than 5% at tow years post-diagnosis. The fact that this figure has not changed significantly over the last 2-3 decades urges for more detailed studies to elaborate the pathological basis of GBM.
Recently, the cancer stem cell (CSC) model has been applied on GBM and provided some interesting findings concerning the complex organization and interaction among cancer cells within the GBM mass. This may offer an alternative approach that has a significant positive impact on GBM management in terms of providing novel prognostic and therapeutic tools.
Recent data, using certain markers such as CD15, CD133 and NG2, indicate that the simplistic picture of the CSC model may not be accurate. However, these new findings have imposed new questions that may lead to adopting novel cellular and molecular approaches.
(محمد طلال فاعل الميهني)
Comparative Genomic Hybridyzation
No collaborators listed
Associated News Items
Heywood RM, Marcus HJ, Ryan DJ, Piccirillo SG, Al-Mayhani TM, Watts C (2012), “A review of the role of stem cells in the development and treatment of glioma.” Acta Neurochir (Wien) 154(6):951-69; discussion 969 Details
Al-Mayhani MT, Grenfell R, Narita M, Piccirillo S, Kenney-Herbert E, Fawcett JW, Collins VP, Ichimura K, Watts C (2011), “NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature.” Neuro Oncol 13(8):830-45 Details
Kenney-Herbert EM, Ball SL, Al-Mayhani TM, Watts C (2011), “Glioblastoma cell lines derived under serum-free conditions can be used as an in vitro model system to evaluate therapeutic response.” Cancer Lett 305(1):50-7 Details
Fael Al-Mayhani TM, Ball SL, Zhao JW, Fawcett J, Ichimura K, Collins PV, Watts C (2009), “An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours.” J Neurosci Methods 176(2):192-9 Details
Fael Al-Mayhani TM, Petalidis L, Kenney-Herbert E, Grenfell R, Ichimura K, Collins P, Watts C. (2009), “NG2 expression identifies a cell population capable of maintaining tumour growth in glioblastoma. ” In: National Cancer Research Institute (NCRI) Cancer Conference 2009; 4 Oct - 7 Oct 2009; Birmingham, UK. NCRI; Oct 2009. Abstract BOA18.
Talal M. Fael Al-Mayhani, Richard Grenfell, Lawrence Petalidis, Emma Kenney-Herbert, Koichi Ichimura, Peter Collins, Colin Watts (2009), “NG2 EXPRESSION ESTABLISHES A LINK BETWEEN NEURAL PRECURSORS AND CANCER STEM CELLS IN GLIOBLASTOMA” Neuro Oncology 11(6):877
Emma Kenney-Herbert, Siolian R. Ball, Talal M. Fael Al-Mayhani, Colin Watts (2008), “VEGF autocrine signalling maybe involved in proliferation of tumour initiating cells” British Journal of Neurosurgery; 22(3): p321
Talal M Fael Al-Mayhani, Siolian LR Ball, Jing-Wei Zhao, James Fawcett, Koichi Ichimura, Peter V Collins, Colin Watts (2008), “Glioblastoma cell lines that express markers associated with NG2 lineage” British Journal of Neurosurgery; 22(3): p318
Talal M. Fael Al-Mayhani, Siolian Ball, Jing-Wei Zhao, Peter Collins, Colin Watts (2007), “Sphere formation is not essential for the derivation of tumour-initiating stem-like cells from human glioblastoma specimens” Neuron Glia Biology 3, Suppl. 1, p S126-127